A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.
AUTOR(ES)
Little, A
RESUMO
The first long-term double-blind placebo controlled trial of high dose lecithin in senile dementia of the Alzheimer type is reported. Fifty one subjects were given 20-25 g/day of purified soya lecithin (containing 90% phosphatidyl plus lysophosphatidyl choline) for six months and followed up for at least a further six months. Plasma choline levels were monitored throughout the treatment period. There were no differences between the placebo group and the lecithin group but there was an improvement in a subgroup of relatively poor compliers. These were older and had intermediate levels of plasma choline. It is suggested that the effects of lecithin are complex but that there may be a "therapeutic window" for the effects of lecithin in the condition and that this may be more evident in older patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1028443Documentos Relacionados
- Cognitive effects of high-dose naltrexone in patients with probable Alzheimer's disease.
- Double-blind, crossover, placebo-controlled clinical trial with clobetasol propionate in desquamative gingivitis
- Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
- Effects of conventional vs high-dose rocuronium on the QTc interval during anesthesia induction and intubation in patients undergoing coronary artery surgery: a randomized, double-blind, parallel trial
- A double-blind controlled trial of high dose methyl prednisolone in multiple sclerosis.
